Abstract: The present invention is related to a method for preparing an amorphous metal fluoride of the formula MX+FX?? comprising the steps of a) providing a precursor, whereby the precursor comprises a structure having a formula of Mx+F(x??)?yBy; and b) reacting the precursor with a fluorinating agent generating the amorphous metal flouride having a formula of Mx+Fx??, whereby M is selected from the group comprising metals of the second, third and fourth main group and any subgroup of the periodic table, B is a coordinately bound group; x is any integer of 2 or 3; y is any integer between 1 and 3; ? is 0 to 0.1; and x??>y.

Abstract: The present invention is related to a method for preparing an X-ray amorphous or weakly crystalline metal oxide fluoride of a composition represented by the formula Ma+ObFc comprising the steps of b) providing a precursor, whereby the precursor is a fluorinated metal compound having a composition which is represented by the formula Ma+F(a?d)BdLxb) converting the precursor into an metal oxide/hydroxide fluoride; and c) calcinating the metal oxide/hydroxide fluoride having the formula Ma+OcHfFc to generate the X-ray amorphous or weakly crystalline metal oxide fluoride of the formula Ma+ObFc, whereby M is selected from the group comprising metals of the first, second, third and fourth main group and any subgroup of the periodic table; B is a group or an anion which is selected from the group comprising alkoxide, enolates, alkyl, chloride, bromide, iodide, nitrate, and organic acid anions; B is preferably an alkoxy group; L is a solvent other than water; a is any integer of 1, 2, 3, 4, 5 or 6, preferably 2 or 3;

Abstract: The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [—RF(CH2)nCR1—CR2—]x, wherein RF is a linear or branched perfluorinated alkyl chain C2F5 to C12F23, R1 and R2 are independently selected from the group consisting of H, CH3, C2H5 and C3H7, n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.

Abstract: The present invention is related to a method for preparing an amorphous metal fluoride of the formula MX+FX-? comprising the steps of a) providing a precursor, whereby the precursor comprises a structure having a formula of Mx+F(x-?)-yBy; and b) reacting the precursor with a fluorinating agent generating the amorphous metal flouride having a formula of Mx+Fx-?, whereby M is selected from the group comprising metals of the second, third and fourth main group and any subgroup of the periodic table, B is a coordinately bound group; x is any integer of 2 or 3; y is any integer between 1 and 3; ? is 0 to 0.1; and x??>y.

Abstract: The invention relates to pharmaceutical compositions which are incorporated into the skin with the aid of novel microaggregates as carriers. The object of the invention is to make available pharmacological active compounds in a biologically and chemically inert carrier for therapeutic and diagnostic administration to the skin or for systemic administration, and in this way to make deeper penetration into the skin or transdermal transport possible. According to the invention, this is effected by means of a pharmaceutical composition for topical administration, which contains asymmetric lamellar aggregates, consisting of phospholipids, pharmacological active compounds and fluorocarbons or fluorocarbon mixtures, the proportion of fluorocarbon being in the range from 1 to 100% weight/volume, in a pharmaceutical excipient which is suitable for topical administration.

Abstract: The invention relates to a cosmetic for assisting the transport of oxygen in the skin, a process for its preparation and the use thereof. The problem with the known cosmetics is the inadequate oxygen supply to the skin and the adjoining tissue. The object of the invention is therefore to get through the horny layer of the skin and the epidermis by penetration processes in order to increase the oxygen concentration in the dermal area and adjoining tissue and to activate metabolic processes. According to the invention, this is effected by a cosmetic containing asymmetric lamellar aggregates, consisting of phospholipids and oxygen-laden fluorocarbon or fluorocarbon mixture, the amount of fluorocarbon being in the range from 0.2 to 100% weight/volume, in a carrier suitable for dermatological use. Preparation is effected by emulsification of the corresponding constituents, and use in ointments, creams, lotions, waters, alcoholic extracts, pastes, powders, gels, tinctures or on dressings and plasters or in a spray.

Abstract: The invention relates to a preparation for topical use, having light protection properties and in a special application form. In the known light protection agents containing the naturally occurring active compound melanin, the problem is inadequate transport of the melanin to its site of action. According to the invention, this problem is solved by a preparation for topical use which is characterised in that it contains melanin, dissolved or dispersed in one or more fluorocarbons, which are present as asymmetric lamellar phospholipid aggregates in an aqueous system together with a phospholipid, with a particle size of the aggregates in the range from 200 to 3000 nm.

Abstract: The invention relates to a dermatological agent for assisting the transport of oxygen in the skin, a process for its preparation and the use thereof. The problem with the known dermatological agents is the inadequate supply of oxygen to the skin and the adjoining tissue. The object of the invention is therefore to get through the horny layer of the skin and the epidermis by penetration processes in order to increase the oxygen concentration in the dermal area and adjoining tissue and to activate metabolic processes. According to the invention, this is effected by means of a dermatological agent containing asymmetric lamellar aggregates, consisting of phospholipids and oxygen-laden fluorocarbon or fluorocarbon mixture, the amount of fluorocarbon being in the range from 0.2 to 100% weight/volume, in a carrier which is suitable for dermatological use.

Abstract: Straight chain perfluoroolefins compounds of medium length with terminal or double bonds and a minor proportion of trifluoromethyl side chains or mixtures of such perfluoroolefins with perfluoro paraffins of equal chain length and corresponding structure, the perfluoroolefins being present in the mixture in an amount of 40 to 70%. The compounds are valuable as highly reactive intermediate products in the production of surface active agents. The compounds are made by subjecting a highly fluorinated organic compound to degradation by means of a high energy radiation of a density of 0.3 to 3.0 W/cm.sup.2 effected in a radiation chamber which has been subjected to a preceding rinsing with an inert gas or with a monomeric highly fluorinated organic compound.

Abstract: Processes for the separation of a potassium salt of a perfluoroalkanoic acid having at least 1 and at most 12 carbon atoms per molecule or a mixture of potassium salts of a homologous mixture of the said perfluoroalkanoic acids from an aqueous solution that also contains a substantial proportion of one or more watersoluble salts of inorganic acids which process comprises extracting at room temperature the said aqueous solution with an organic solvent which is at least partially miscible with water and in which potassium salts of the said perfluoroalkanoic acids are soluble, the said organic solvent being selected from the group consisting of alkanols having at least 3 and at most 5 carbon atoms per molecule, ketones having at least 3 and at most 7 carbon atoms per molecule, N,N-dimethylformamide and dimethyl sulfoxide, and subsequently recovering the potassium salt of the perfluoroalkanoic acid or mixture of potassium salts of the homologous mixture of perfluoroalkanoic acids.